| Document |
Document Title |
|
WO/2024/068853A1 |
The present invention relates to an improved synthesis of Otviciclib (N-{4-[l-(2,6-Dichloro-4- sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-lH-pyraz
olo[3,4-d]pyrimidin-6- ylmethyl]-phenyl}-2-diethylamino-acetamide) and its deriva...
|
|
WO/2024/031002A1 |
This disclosure includes pesticidal compounds, compositions, and related agricultural methods.
|
|
WO/2024/015861A1 |
Provided herein are methods of preparation of compound 101. Also provided are intermediate compounds useful in the preparation of compound 101, and methods of preparation of those intermediate compounds.
|
|
WO/2024/006402A1 |
The present disclosure relates to compounds comprising histone deacetylase 3 (HDAC3) targeting ligand conjugated to a Degron binding E3 ubiquitin ligase to achieve recruitment of the E3 ubiquitin ligase to HDAC3. Further disclosed compos...
|
|
WO/2023/250107A1 |
The present disclosure relates generally to methods for the preparation of Compound (I-1): I-1 or a stereoisomer or mixture of stereoisomers thereof, or salt of each thereof, as well as compounds and salts which are useful in the synthes...
|
|
WO/2023/223055A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/160344A1 |
Disclosed are a NO donor compound, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof. The structure of the compound is represented by formula I. The NO donor compound and the pharmaceutical comp...
|
|
WO/2023/144798A1 |
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid ...
|
|
WO/2023/141648A1 |
Disclosed are compounds, including 2-fluoroethyl procarbazine compounds, pharmaceutical compositions comprising the compounds, and methods of treating cancers with the compounds and particularly for treating cancers that are O6-methylgua...
|
|
WO/2023/107557A1 |
Pyrazolo[1,5-a]pyrimidines are disclosed. These compounds may be useful in the treatment of neurological disorder, including frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, limbic-predominant age-related T...
|
|
WO/2023/098592A1 |
The present invention provides a carbon-loaded iron-based catalyst, and a preparation method thereof and a use. The preparation method comprises dissolving ferric chloride in water, adding activated carbon, adding sodium hydroxide at 60-...
|
|
WO/2023/085645A1 |
The present invention relates to a ramalin derivative and use thereof for the prevention or treatment of neurodegenerative diseases and, more specifically, to use of a ramalin derivative for the prevention or treatment of neurodegenerati...
|
|
WO/2023/062053A1 |
The invention relates to a process for synthesizing bis(2-nitratoethyl)dinitroxamide which comprises reacting bis-hydroxyethyloxamide with nitric acid in the presence of an oleum solution. The invention also relates to a process for prep...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/040759A1 |
A crystalline modification I of N'-tert-butyl-N'- (3, 5-dimethylbenzoyl) -3-methoxy-2-methylbenzohydrazide (Methoxyfenozide) is provided. There is also provided a process for preparing this crystalline form. The use of this novel crystal...
|
|
WO/2023/027654A1 |
The invention relates to an agent containing carboxylic acid hydrazide-coumarin hybrid compounds with anti-inflammatory and anticonvulsant effects with various biological activity potentials.
|
|
WO/2023/022231A1 |
The present invention provides a compound for treating or preventing a viral infection. The present invention pertains to a compound represented by formula (1) [wherein: R1 is a group represented by formula (AA); Y is a group represent...
|
|
WO/2022/270467A1 |
The purpose of the present invention is to provide a novel hydrazide compound. It is additionally the purpose of the present invention to provide: a curable resin composition that contains the hydrazide compound and that exhibits excepti...
|
|
WO/2022/250620A1 |
The present invention relates to a new crystalline polymorph of benserazide hydrochloride. More specifically, the invention relates to novel Form H of benserazide hydrochloride, process for preparing the novel form of benserazide hydroch...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/223696A1 |
The invention provides a process for synthesizing N-alkyl-N-phenyl hydrazine which is devoid of any organic solvents and can be carried out at lower temperatures. The process is environmental-friendly and gives better yield and high puri...
|
|
WO/2022/197690A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (H...
|
|
WO/2022/165382A1 |
The invention provides compositions and methods for the treatment of anxiety, panic disorder, seasonal affective disorder (SAD), and other psychological disorders. In particular, the invention provides combination treatment methods invol...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/107139A1 |
The present invention is directed to a process for the preparation of a hydrazine derivative by reaction of the corresponding oxirane with hydrazine, that uses as only solvent toluene. The process provides excellent yields and purities a...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2021/252640A1 |
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...
|
|
WO/2021/246479A1 |
One purpose of the present invention is to provide a novel dihydrazide compound. Another purpose of the present invention is to provide: a curable resin composition which contains the above-described dihydrazide compound and exhibits exc...
|
|
WO/2021/200694A1 |
[Problem] To provide a novel compound that has read-through activity and is useful as an agent for preventing or treating nonsense-mutation genetic disorders. [Solution] One embodiment of the present invention provides a compound represe...
|
|
WO/2021/187748A1 |
According to an aspect, a method for selectively modifying nucleotides comprises a step for reacting nucleotides and a compound of formula 1 in the presence of a rhodium catalyst, wherein the O6 position of a guanine among the four bases...
|
|
WO/2021/152564A1 |
Disclosed is a method for purifying a crude adiponitrile stream by differential volatility comprising separating at least a portion of the components of the crude adiponitrile stream by flashing vapor from a liquid film.
|
|
WO/2021/125307A1 |
The present invention addresses the problem of providing a novel crystal. A crystal of 3-hydroxy-N'-(1,3-dimethylbutylidene)-2-naphthoic acid hydrazide having a maximum intensity peak at 6.9° as a diffraction angle (2θ) in a powder X-r...
|
|
WO/2021/125306A1 |
The present invention addresses the problem of providing a novel crystal. A crystal of 3-hydroxy-N'-(1, 3-dimethylbutylidene)-2-naphthoic acid hydrazide which has a peak with the maximum intensity at a diffraction angle (2θ) of 6.1 ± 0...
|
|
WO/2021/119606A1 |
The disclosure provides, inter alia, safe and environmentally-friendly methods, such as flow chemistry, to synthesize isocyanates, such as methylene diphenyl diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, isophorone diis...
|
|
WO/2021/111022A1 |
The present invention relates to to sulfated phenylhydrazide derivatives of formula (I) as antiviral agents. Said compounds are therefore useful for the prevention and/or treatment of viral diseases such as the disease caused by Ebola vi...
|
|
WO/2021/089011A1 |
Provided are a compound with a bishydrazide structure represented by formula I, and a preparation method therefor and the use thereof. The compound with a bishydrazide structure can enhance the activity of intestinal stem cells, promote ...
|
|
WO/2021/079069A1 |
The present invention relates to novel energetic salts of formula C+A-, wherein: C+ is a cation derived from an amino acid; A- is an energetic nitrogen-containing anion chosen among the anions derived from dinitramide, trinitromethane (N...
|
|
WO/2021/071493A1 |
The present disclosure describes multi-fluid kits for printing three-dimensional green body objects, three-dimensional printing kits, and methods of three-dimensional printing. In one example, a multi-fluid kit for printing a three-dimen...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2020/245468A1 |
The present invention relates to compounds useful as modulators of sirtuins, in particular as activators of SIRT1. Furthermore, the invention refers to the medical use of such compounds, in particular in the prevention and/or treatment o...
|
|
WO/2020/184336A1 |
Provided is a liquid metal complex having oxygen-absorbing ability and containing: a cobalt acacene complex or a derivative thereof; and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are pai...
|
|
WO/2020/180823A1 |
Presented herein, in certain aspects, are methods of preventing, reducing, delaying and treating post-operative cognitive dysfunction, or one or more symptoms thereof, by administering a compound disclosed herein to a subject prior to, d...
|
|
WO/2020/180821A1 |
Presented herein, in certain aspects, are methods of treating or preventing obesity, assisting or inducing weight loss, suppressing appetite, or inhibiting weight gain in a subject by administering a compound of the invention to a subject.
|
|
WO/2020/179671A1 |
This invention provides: a curable resin composition including a specific polymer precursor, a nonionic compound B, and at least one compound selected from the group consisting of a polymerizable compound and a photosensitive compound, w...
|
|
WO/2020/169682A1 |
The present invention relates to compounds of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, their use as a drug, in particular as antibacterial agent, notablyforpreventingand/or treating...
|
|
WO/2020/102936A1 |
A method for preparing a covalent organic framework (COF) material and a method for reversible condensation polymerization/termination polymerization. The COF material prepared by the present method shows high crystallinity, high specifi...
|
|
WO/2020/094440A1 |
The invention relates to a process for the synthesis of aryl hydrazinesof formula I or a salt thereof, which process comprises subjecting an arene of formula II to a coupling reaction with hydrazine or a derivative thereof, wherein the c...
|
|
WO/2020/047231A9 |
Provided are mixtures of dexamethasone- N-methacryloylglycylglycyl hydrazide (MA-Gly-Gly-NHN=Dex) monomers enriched in a desired diastereomer, and polymer compositions of same. Also provided are methods of treating inflammatory condition...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
